Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

770011

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dental Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to improve information for patients who may be exempt from dental charges.
tabling member constituency	Hertsmere
tabling member printed	Oliver Dowden
uin	107696
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>The Department makes available to all National Health Service dental practices a patient leaflet which includes information on how to claim free treatment and reminds practices annually of the need to display the leaflets. Information is also set out on NHS Choices and can be found here:</p><p><a href="http://www.nhs.uk/chq/Pages/1786.aspx?CategoryID=74&amp;SubCategoryID=742" target="_blank">www.nhs.uk/chq/Pages/1786.aspx?CategoryID=74&amp;SubCategoryID=742</a></p><p>Information on NHS Choices is regularly reviewed.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2017 16:48:18 answering member 4067 label Biography information for Steve Brine
tabling member	4441 label Biography information for Oliver Dowden

770014

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Obesity: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the cost to the public purse of denying or delaying treatment for patients requiring bariatric surgery.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	107710
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>NHS England has not made an assessment of the cost or delaying treatment for patients requiring bariatric surgery.</p><p> </p><p>Clinical commissioning groups (CCGs) have a statutory responsibility to commission services which meet the needs of their local population. When developing their associated commissioning policies and treatment criteria, we would expect CCGs to take into account any relevant current guidance, and consider the wider context of their actions which may include the costs incurred as a result of setting criteria which may deny or delay treatment for patients requiring bariatric surgery. Treatment decisions should always be made by doctors based on patients’ clinical needs.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2017 16:48:44 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

770015

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Commissioning Groups
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that clinical commissioning groups follow National Institute for Health and Care Excellence guidelines.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	107711
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>As statutory bodies, we would expect clinical commissioning groups (CCGs) to take account of National Institute for Health and Care Excellence (NICE) and best practice guidance when developing policies and treatment criteria for the services they commission. There is no formal mechanism for requiring that CCGs follow NICE guidelines.</p><p> </p><p>CCGs are responsible for working with their local communities to understand the needs of the local populations and make decisions about how best to commission services that meet those needs, in partnership with other local commissioners and organisations.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2017 16:50:13 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

770016

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Obesity: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the potential merits of NICE guidance on bariatric surgery (CG189).
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	107726
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) issued a clinical guideline on the identification, assessment and management of obesity in 2014 that makes recommendations on the use of bariatric surgery.</p><p> </p><p>NICE’s guideline recommends bariatric surgery as an option for people with obesity if all of the following criteria are fulfilled:</p><p> </p><p>- They have a body mass index of 40 kg/m2 or more, or between 35 kg/m2 and 40 kg/m2 and other significant diseases (for example, type 2 diabetes or high blood pressure) that could be improved if they lost weight;</p><p>- All appropriate non-surgical measures have been tried but the person has not achieved or maintained adequate, clinically beneficial weight loss;</p><p>- The person has been receiving or will receive intensive management in a tier 3 service;</p><p>- The person is generally fit for anaesthesia and surgery; and</p><p>- The person commits to the need for long-term follow-up.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2017 16:50:23 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

770046

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many women were admitted to hospital with severe ovarian hyperstimulation syndrome following IVF treatment in (a) 2015 and (b) 2016.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107676
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>NHS Digital has advised that this data is not collected centrally.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 18/10/2017 14:22:17 answering member 1542 label Biography information for Philip Dunne
tabling member	3958 label Biography information for Fiona Bruce

770083

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Department of Health: Telephone Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many 0345 telephone numbers are in use by his Department; and how much revenue has been generated by each such telephone number in each year since 2010.
tabling member constituency	Oldham West and Royton
tabling member printed	Jim McMahon
uin	107734
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>The Department does not use premium rate telephones lines where any accruals are made by the Department, and has not done so over the past five years.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 18/10/2017 11:39:45 answering member 1542 label Biography information for Philip Dunne
tabling member	4569 label Biography information for Jim McMahon

769231

registered interest
date	12/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the action taken by the Medicines and Healthcare Products Regulatory Agency in 2012–13 to undertake enhanced pharmacovigilance alongside routine signal detection for the HPV vaccine was effective in preventing unfounded safety concerns; and if not, whether they will ask the Medicines and Healthcare Products Regulatory Agency to conduct further heightened pharmacovigilance at specific centres to assess those who suspect they have an adverse reaction to the HPV vaccination.
tabling member printed	The Countess of Mar
uin	HL1965
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) put in place an enhanced form of pharmacovigilance for the human papillomavirus (HPV) vaccine when the immunisation programme first commenced in 2008. This was because, at the time, the United Kingdom was the first country to implement a nationwide immunisation programme with the Cervarix brand of HPV vaccine. This enhanced form of pharmacovigilance was based primarily on the evaluation of general practice-derived electronic health record data, alongside Yellow Card reports. This has been effective in allowing the MHRA to determine that the reporting rate of particular suspected side effects, adjusted for under-reporting, is within the range of the expected natural incidence in the absence of HPV vaccination. As with all vaccines and medicines, the MHRA keeps the safety of HPV vaccine under continual review.</p><p>The Commission on Human Medicines has advised that available evidence does not support a link between HPV vaccination and the development of chronic illnesses, and reviews of HPV vaccine safety undertaken by international health authorities have reached similar conclusions. Most recently, in July 2017, the World Health Organization’s vaccine safety committee concluded that it has found no new adverse events of concern for HPV vaccine based on many very large, high quality studies.</p><p> </p><p>The clinical assessment of individual patients remains the responsibility of their doctors and other healthcare providers.</p><p><strong><br> </strong></p><p> </p> answering member printed Lord O'Shaughnessy question first answered 18/10/2017 15:41:55 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

769232

registered interest
date	12/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether double-blind placebo-controlled clinical trials were used by marketing authorisation holders for the testing of HPV vaccines prior to approval by the Medicines and Healthcare Products Regulatory Agency.
tabling member printed	The Countess of Mar
uin	HL1966
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>The Human Papilloma Virus (HPV) vaccines available in the European Union were authorised by the European Medicines Agency, and a detailed summary of its evaluation of the pre-licensing clinical trials for each vaccine is available in the European public assessment reports. These reports confirm that randomised, double-blind, placebo-controlled trials were considered in the evaluation of each HPV vaccine prior to approval.</p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy question first answered 18/10/2017 15:42:28 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

769233

registered interest
date	12/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Side Effects
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether it is possible to inform the Medicines and Healthcare Products Regulatory Agency of signs and symptoms that arise after a Yellow Card report has been submitted; and if so, how this should be done.
tabling member printed	The Countess of Mar
uin	HL1967
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>Additional information can be submitted directly by the original reporter or by the pharmaceutical company as new information becomes available following the submission of the original report. Furthermore, follow-up information is frequently requested by the Medicines Healthcare products Regulatory Agency (MHRA) in order to assess Adverse Drug Reaction (ADR) reports more effectively and to improve the quality of information on the database.</p><p> </p><p>Once a Yellow Card (YC) report is submitted and entered onto the database, an acknowledgment letter or email is sent to the reporter to confirm receipt and advise of the ADR reference number.</p><p> </p><p>Additional information can be provided to the MHRA at any time following the submission of a YC report. The ADR reference number is required together with any additional information to ensure that this is added to the correct report. However, every effort is made to identify the correct report in instances where the ADR reference number has not been provided.</p><p> </p><p> </p> answering member printed Lord O'Shaughnessy question first answered 18/10/2017 15:40:27 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

769703

registered interest
date	12/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Private Sector
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost to the public purse was of treatments provided to private patients in NHS hospitals in each of the last 10 years for which figures are available.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	107454
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>There should not be a net cost to the public purse of treating private patients. National Health Service organisations can treat private patients but only for the purpose of generating income to fund treatment of NHS patients.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 18/10/2017 14:28:01 answering member 1542 label Biography information for Philip Dunne
tabling member	4418 label Biography information for Justin Madders